A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors

ABSTRACT: This is a phase 1, multi-center, dose escalation, open-label study to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of JAB-3068 in adult patients with advanced solid.

DISEASE(S): Other Metastatic Solid Tumors,Nsclc,Colorectal Cancer,Non-small Cell Lung Cancer,Advanced Solid Tumor,Esophageal Cancer,Head And Neck Cancer

PROVIDER: 2272421 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR